Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Journal Articles

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Fnu Amisha, Syeda Saba Kareem, Kiranpreet Kaur, Biwei Cao, Samuel Reynolds, Yumeng Zhang, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Lubomir Sokol, Bijal Shah, Frederick Locke, Julio Chavez, Michael Jain

Blood (2025) 146 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2025-5512

Published: 2025

Journal Articles

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Abida Babu, syeda mahrukh naqvi, Julio Chavez, Bijal Shah, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Yumeng Zhang, Javier Pinilla-Ibarz, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2025-1825

Published: 2025

Journal Articles

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

Sara Niyazi, Ahmed Arfa, Tobi Ozoya, Kimberly Ward, Lalith Roopesh, Jeffrey West, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol, Dietrich Werner Idiaquez, Christopher Ryder, Yumeng Zhang

Blood (2025) 146 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2025-3644

Published: 2025

Journal Articles

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Sushmita Khadka, Anushi Patel, Jonathan Zhao, Leidy Isenalumhe, Lubomir Sokol, Sameh Gaballa, Yumeng Zhang, Celeste Bello, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2025-1882

Published: 2025

Journal Articles

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona, Shannen Whiddon, Janice Bennett, Anthony Suda, Bijal Shah, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Sameh Gaballa, Javier Pinilla-Ibarz, Frank Glass, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2025-1881

Published: 2025

Journal Articles

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Yumeng Zhang, Hayder Saeed, Amin Azem, Jose Sandoval-Sus, Fatima Tuz Zahra, Kavita Ghia, Abu-Sayeef Mirza, Bijal Shah, Celeste Bello, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2025-7161

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis

Lalith Roopesh, Kimberly Ward, Fnu Amisha, Shannen Whiddon, Janice Bennett, Hien Liu, Lewis Glass, Lubomir Sokol, Yumeng Zhang

Blood (2025) 146 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2025-5427

Published: 2025

Journal Articles

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian, Mahrukh Naqvi, Qiangxing Mo, Ling Zhang, Rikesh Makanji, Yumeng Zhang, Ning Dong, Leidy Lismeris Isenalumhe, Sameh Gaballa, Julio C. Chavez, Bijal D Shah, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2024-205173

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

Journal Articles

Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma

Sara Niyazi, Xiaoqing Yu, Carly Harro, Lewis Glass, Lubomir Sokol, Jose Conejo-Garcia, Ling Zhang, Yumeng Zhang

Blood (2024) 144 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2024-202658

Published: 2024

Journal Articles

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Mohammad Ammad Ud Din, Katherine Tobon, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Ariel Grajales-Cruz, Kenneth H. Shain, Lubomir Sokol, Bijal D Shah, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2024-208769

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Aditi Saha, Junmin Whiting, Mohammad Ammad-ud-din, Cole Powell, Kristen Flores, Felix Sanjay, Humaira Sarfraz, Khushali Jhaveri, Michael V. Jaglal, Katherine Tobon, Hayder Saeed, Celeste M. Bello, Bijal D. Shah, Leidy Lismeris Isenalumhe, Javier Pinilla-Ibarz, Lubomir Sokol, Julio C Chavez, Ning Dong

Blood (2023) 142 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2023-188211

Published: 2023

Journal Articles

A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses

Ning Dong, Shubham Jaiswal, Sushmita Khadka, Cathelencia Francisque, Yumeng Zhang, Lewis Glass, Kaaron Benson, Hien Liu, Lubomir Sokol

Blood (2023) 142 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2023-191313

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only